Creating a New Diversified

Biopharmaceutical Company
The Combination of AbbVie and Allergan

Investor Presentation
June 25, 2019
NO OFFER OR SOLICITATION
This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the
solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of
applicable law. In particular, this presentation is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S.
Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the acquisition are anticipated to
be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The acquisition will be made solely
by means of the Scheme Document (or, if applicable, the Takeover Offer document), which will contain the full terms and conditions of the acquisition, including details with respect to the AbbVie
shareholder vote in respect of the acquisition. Any decision in respect of, or other response to, the acquisition, should be made only on the basis of the information contained in the Scheme
Document.
IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC
In connection with the proposed Acquisition, Allergan will file with the Securities Exchange Commission (the “SEC”) a Proxy Statement, which will include the Scheme Document. BEFORE MAKING
ANY VOTING DECISION, ALLERGAN'S SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT, INCLUDING THE SCHEME DOCUMENT, AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED
WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES TO THE PROPOSED ACQUISITION. Allergan’s shareholders and
investors will be able to obtain, without charge, a copy of the Proxy Statement, including the Scheme Document, and other relevant documents filed with the SEC (when available) from the SEC’s
website at http://www.sec.gov. Allergan shareholders and investors will also be able to obtain, without charge, a copy of the Proxy Statement, including the Scheme Document, and other relevant
documents (when available) by directing a request by mail or telephone to Allergan, or from Allergan’s website.
PARTICIPANTS IN THE SOLICITATION
Allergan and certain of its directors and executive officers and employees may be considered participants in the solicitation of proxies from the shareholders of Allergan in respect of the
transactions contemplated by the Scheme Document. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders of
Allergan in connection with the proposed transactions, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Scheme Document when
it is filed with the SEC. Information regarding Allergan’s directors and executive officers is contained in Allergan’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and its
Proxy Statement on Schedule 14A, dated March 22, 2019, which are filed with the SEC, and certain of Allergan’s Current Reports on Form 8-K, which were filed with the SEC on February 19, 2019,
March 22, 2019 and May 1, 2019.
FORWARD LOOKING STATEMENTS
This presentation contains certain forward-looking statements with respect to a possible acquisition involving AbbVie and Allergan and AbbVie’s, Allergan’s and/or the combined group’s estimated
or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for AbbVie and, following the acquisition, if
completed, the combined group. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. These forward-
looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties
include, but are not limited to, the possibility that a possible acquisition will not be pursued, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other
conditions to the possible acquisition, adverse effects on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares and on AbbVie’s or Allergan’s operating results because
of a failure to complete the possible acquisition, failure to realize the expected benefits of the possible acquisition, failure to promptly and effectively integrate Allergan’s businesses, negative
effects relating to the announcement of the possible acquisition or any further announcements relating to the possible acquisition or the consummation of the possible acquisition on the market
price of AbbVie’s shares of common stock or Allergan’s ordinary shares, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the possible
acquisition, general economic and business conditions that affect the combined companies following the consummation of the possible acquisition, changes in global, political, economic, business,
competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals and competitive
developments. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie’s or, as the case may be, Allergan’s experience and perception of
historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve
known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking
statements in this presentation could cause AbbVie’s plans with respect to AbbVie, Allergan’s or AbbVie’s actual results, performance or achievements, industry results and developments to differ
materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no
assurance can be given that such expectations will prove to have been correct and persons reading this presentation are therefore cautioned not to place undue reliance on these forward-looking
statements which speak only as at the date of this presentation. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie is set
forth in Item 1A, “Risk Factors,” in AbbVie’s 2018 Annual Report on Form 10-K, which has been filed with the SEC, the contents of which are not incorporated by reference into, nor do they form
part of, this presentation. Additional information about economic, competitive, governmental, technological and other factors that may affect Allergan is set forth in Item 1A, “Risk Factors,” in
Allergan’s 2018 Annual Report on Form 10-K, which has been filed with the SEC, the contents of which are not incorporated by reference into, nor do they form part of, this presentation.
Any forward-looking statements in this presentation are based upon information available to AbbVie and/or its board of directors as of the date of this presentation and, while believed to be true
when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, neither AbbVie or any member of its board of directors undertakes any obligation to update any
forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes
in expectations. All subsequent written and oral forward-looking statements attributable to AbbVie or its board of directors or any person acting on behalf of any of them are expressly qualified in
their entirety by this paragraph.

2
STATEMENT REQUIRED BY THE IRISH TAKEOVER RULES
The directors of AbbVie accept responsibility for the information contained in this presentation. To the best of the knowledge and belief of the directors of AbbVie (who have taken all reasonable
care to ensure that such is the case), the information contained in this presentation for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect
the import of such information.
DEALING DISCLOSURE REQUIREMENTS
Under the provisions of Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”), if any person is, or becomes, ‘interested’ (directly or indirectly) in, 1% or
more of any class of ‘relevant securities’ of AbbVie or Allergan, all ‘dealings’ in any ‘relevant securities’ of AbbVie or Allergan (including by means of an option in respect of, or a derivative
referenced to, any such ‘relevant securities’) must be publicly disclosed by not later than 3:30 pm (Irish time) on the ‘business’ day following the date of the relevant transaction. This requirement
will continue until the date on which the Scheme becomes effective or on which the ‘offer period’ otherwise ends. If two or more persons co-operate on the basis of any agreement, either express
or tacit, either oral or written, to acquire an ‘interest’ in ‘relevant securities’ of AbbVie or Allergan, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.
Under the provisions of Rule 8.1 of the Irish Takeover Rules, all ‘dealings’ in ‘relevant securities’ of Allergan by AbbVie or ‘relevant securities’ of AbbVie by Allergan, or by any party acting in concert
with either of them, must also be disclosed by no later than 12 noon (Irish time) on the ‘business’ day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose ‘relevant securities’ ‘dealings’ should be disclosed, can be found on the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie.
NO PROFIT FORECAST / ASSET VALUATIONS
No statement in this presentation is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be
greater or lesser than those for the relevant preceding financial periods for AbbVie or Allergan as appropriate. No statement in this presentation constitutes an asset valuation.
GENERAL
Appendix I to the Rule 2.5 announcement issued jointly by AbbVie and Allergan on June 25, 2019 (the “Rule 2.5 Announcement”) contains further details of the sources of information and bases of
calculations set out in this presentation.
This presentation contains certain statements as to estimated synergies arising from the Acquisition. There are various material assumptions underlying the synergies estimate which may result in
the synergies being materially greater or less than estimated. The estimates should therefore be read in conjunction with the bases and assumptions for these synergy numbers which are set out in
Appendix I of the Rule 2.5 Announcement. The synergies have been reported on in accordance with Rule 19.3(b) of the Irish Takeover Rules by (i) PricewaterhouseCoopers and (ii) Morgan Stanley.
Copies of their respective reports are included in Appendix IV and Appendix V to the Rule 2.5 Announcement. The synergy and earnings enhancement statements in this presentation should not be
construed as a profit forecast or interpreted to mean that the earnings of AbbVie and/or Allergan in 2019, or in any subsequent period, would necessarily match or be greater than or be less than
those of AbbVie and/or Allergan for the relevant financial period or any other period.
All references in this presentation: (a) to an entity being the “largest” or similar, are by reference to 2018 publicly reported revenues of that entity and of its peer companies; (b) to 2019 revenue of
the combined company are based on revenue guidance for 2019 provided on recent earnings calls; (c) to 2020 revenues are derived from an average of the following broker estimates: (i) in
relation to AbbVie and Humira revenues: Societe Generale, Atlantic Equities, SVB Leerink, Piper Jaffray, Wolfe Research, Morgan Stanley, BMO, Cowen and Credit Suisse; and (ii) in relation to
Allergan: JP Morgan, Credit Suisse, Guggenheim, RBC, Suntrust, Piper Jaffray, Wells Fargo, Citi, Leerink, Cantor, Cowen, Morgan Stanley; (d) to AbbVie’s anticipated growth relative to peers, are by
reference to estimated revenue compound annual growth rate (CAGR) from 2018-2023 sourced from analysts’ consensus estimates as of June 21, 2019, with GSK revenue estimates sourced from
Bloomberg, and all other peer company revenue estimates sourced from Nasdaq IR. Combined revenue growth for AbbVie (ex-Humira) and Allergan is based on AbbVie’s internally estimated
revenue CAGR for 2018-2023 period. AbbVie considers its peer companies for this purpose to be AZN, GSK, BMY, MRK, JNJ, ROG, SAN, PFE, LLY, GILD, NVS and AMGN.
The release, publication or distribution of this presentation in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this presentation and all other
documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions.
Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities
laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies involved in the proposed Acquisition disclaim any responsibility or liability for the violations of any
such restrictions by any person.
Any response in relation to the Acquisition should be made only on the basis of the information contained in the Scheme Documents or any document by which the Acquisition and the Scheme are
made. Allergan shareholders are advised to read carefully the formal documentation in relation to the proposed Acquisition once the Scheme Documents have been dispatched.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
OR REGULATIONS OF SUCH JURISDICTION.

3
 Creates a New Diversified Biopharmaceutical Company,
Well-Positioned for Sustainable Growth
1 Unique opportunity to acquire attractive and durable growth assets at a highly compelling value

• Leverage AbbVie commercial strength and international infrastructure across Allergan’s therapeutic segments
• Significantly expands AbbVie’s presence in attractive high growth markets
• Brings leadership positions with Medical Aesthetics and Neuroscience; further builds out gastroenterology and women’s health franchises

Provides immediate scale and profitability to AbbVie’s Growth Platform (ex-Humira),

2 with sales of more than $30BN* in 2020 and best-in-industry growth expected well into the next decade
• Following transaction, AbbVie comprised of two high value components:
New AbbVie Growth Platform Humira
 Attractive business, with growing leadership positions across high value  Remains an important component of leading Immunology
therapeutic areas with diversified payors; expected to drive high-single- franchise as new assets launch and expand indications
digit annual revenue growth over the next decade  Generating robust cashflow through U.S. loss of exclusivity in 2023
 Growth Platform will have the R&D capacity for continued significant and beyond; earmarked to rapidly pay down incremental debt
investment in promising, innovative science

3 Deal mitigates impact of 2023 U.S. Humira LOE

• Addresses product concentration concerns and secures attractive growth prospects through the next decade under any
U.S. Humira erosion scenario
• Humira will continue to generate robust cash flow that exceeds requirements for paydown of incremental debt by 2023

4 Potential for substantial shareholder value creation

• Immediately accretive to earnings; expected to contribute 10% accretion to adjusted EPS over the first full year of combination, with peak
accretion of greater than 20%**
• Expect >$2BN of pre-tax synergies and other cost reductions in year 3***, while leaving investments in key growth franchises untouched
• Generates significant operating cash flow to reduce debt, support a growing dividend and pursue additional mid-to-late stage pipeline assets
*Not intended as revenue guidance; See disclosure statement on Slide 3. **The statement that this transaction is earnings accretive should not be interpreted to
mean that the earnings per share in the current or any future financial period will necessarily match or be greater than those for the relevant preceding financial 4
period.***Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules.
Financially Compelling Transaction
• Each Allergan share will be exchanged for $120.30 in cash and 0.8660 share of
combined company (fixed exchange ratio). AbbVie shareholders to own 83% of
AbbVie (on a fully diluted basis) and Allergan shareholders to own 17%

• Total consideration of $188.24 per Allergan share based on AbbVie’s closing

stock price on 6/24/2019. Premium of 45% to Allergan’s closing price on
6/24/2019; compares favorably relative to recent transactions of similar scale
• Transaction ROIC to exceed corporate cost of capital in first full year of
Deal Terms combination, offering 10% earnings accretion in first full year, with peak
accretion of greater than 20%*
• Closing anticipated by early 2020, subject to regulatory and shareholder
approvals and other customary closing conditions
• Upon completion of the transaction, the company will continue to be
incorporated in Delaware and have principal executive offices in
North Chicago, Illinois
• Richard Gonzalez will continue to serve as chairman and CEO through
Humira LOE event in 2023; AbbVie Board of Directors will include two Allergan
board members, including Brent Saunders

Creates Generates >$2BN Significant EPS Accretion:

Significant ROIC to Exceed AbbVie
in Synergies and 10% Accretion Over the First
Cost of Capital Within
Shareholder Cost Savings Full Year of Combination
First Full Year
Value in Year 3* Peaking at >20%**

*Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules. ** The statement
that this transaction is earnings accretive should not be interpreted to mean that the earnings per share in the current or any future financial period will necessarily 5
match or be greater than those for the relevant preceding financial period.
 Allergan Business is a Collection of Highly Attractive,
Durable Growth Assets
$15.7BN
• Opportunity for significant market expansion; very durable cash pay business
MEDICAL
$4.3BN • Botox is leading cosmetic neurotoxin; Allergan has unrivaled product bundle
AESTHETICS • Positioned to deliver strong, durable growth through next decade
MEDICAL
AESTHETICS
BOTOX • Leadership in Migraine, Movement Disorders, Overactive Bladder
$2.0BN • Building a competitive Migraine portfolio anchored on Botox
THERAPEUTICS

Growth MIGRAINE • Vraylar is fastest growing atypical antipsychotic in the U.S. and represents a
NEUROSCIENCE $1.2BN clear blockbuster opportunity
Areas GASTROINTESTINAL •
•
2 oral CGRPs in late-stage development emerging with competitive profiles
Opportunity to link Allergan’s Neuroscience portfolio with AbbVie’s R&D capabilities

GASTROINTESTINAL $1.8BN • Linzess and Viberzi complement AbbVie’s position in Gastrointestinal

• AbbVie will provide critical mass to market-leading IBS franchise

WOMEN’S HEALTH $0.8BN • Market leading oral contraceptive, Lo Loestrin

• Combine with Orilissa to build commercial scale and drive franchise growth

BASE
EYE CARE $2.3BN • Strong, durable cash flows
BUSINESS • Opportunity for further growth through new product investments

• Stable and profitable products in both companies’ Base Businesses

BASE BUSINESS • Very efficient P&Ls
• Strong cash flow generation to deploy back into business

Opportunity to Strengthen Allergan’s Franchises and Drive Incremental Growth with

AbbVie’s Commercial Capabilities and Strong Global Infrastructure

Based on 2018 reported revenue.

Eye Care revenue represents Allergan 2018 Eye Care revenue excluding Restasis revenue of $1.262 billion. 6
 Combined Company Comprised of Diverse Portfolio with
Leadership Positions in Attractive, High-Growth Markets
Immunology Hematologic Medical Neuroscience Other
Oncology Aesthetics Franchises

• Established leadership • Established leadership • Global leadership position • Multiple growth • Women’s Health and
position with Humira position with two first- in large, growing market opportunities Eye Care both large
• Launching differentiated, in-class, foundational • Significant opportunity for • Franchise revenue of opportunities
next-gen therapies assets market expansion >$3BN • HCV represents stable
• Revenue of >$20BN • Revenue of >$5BN, with • Franchise revenue of source of cash flows
strong DD growth >$4BN

HCV

Women’s Health
Key Brands

Eye Care

Other

Pipeline of Attractive Next-Generation Opportunities

Revenue numbers represent 2019 guidance for AbbVie products and 2018 reported product revenue for Allergan. 7
 Combination Creates an Attractive Growth Platform that is
Immediately at Scale with Peers
2018 Revenue ($BN) 2018 Operating Cash Flow ($BN)
$90 $25
82
22
$80
20
$70 $20 19

58
$60 16
54
$15 14
49 13
$50 45
42 42 41 11 11 11
38 10
$40
33 32 $10
29 8
$30 25 24 23 7
22 22 6 6 6 6 5
$20 16 15
$5
3
$10

$0 $0

New AbbVie Growth Platform offers attractive

Transaction Significantly growth potential over the long term
Expands and Diversifies
AbbVie’s Revenue Base Humira cash flows will be used to
pay down incremental debt
*Novartis revenues presented net of the Alcon business unit, which was spun-off in April 2019.2018 Alcon revenues were $7.1B.
Note: Takeda has a Mar. 31 fiscal year end and acquired Shire in Jan. '19. Therefore Shire information is not available for the quarter ended Dec. 31, 2018.
**TAK Revenue is a combination of the 4 traditional quarters of 2018 for Takeda and Shire, with analyst consensus estimate used for Shire for the quarter ended Dec. 31, 2018.
***TAK Op. Cash Flow is a combination of the 4 traditional quarters of 2018 for Takeda and Shire excluding 4Q for Shire because financials nor analyst consensus are available.

8
 AbbVie Comprised of Two High Value Components
Provides immediate scale and profitability to AbbVie’s Growth Platform

AbbVie Today New AbbVie

Growth Humira Humira Growth

Platform $19BN $19BN Platform
$14BN >$29BN

 Humira supports  Approximately 60% of  Less than 40% of total  Standalone scale in 2020
infrastructure and total company sales company sales  Best-in-industry revenue
R&D investment growth prospects
 Funds R&D engine  Generates robust cash
flow up to U.S. LOE in  Strong operating margin
 Supports dividend 2023 and beyond and cash flow
 Supports business  Cash flow supports  Funds R&D engine
development return of capital and  Supports dividend
serves as resource to
pay down debt  Supports business
development

Revenue numbers based on AbbVie and Allergan respective revenue guidance for 2019 provided on recent earnings calls. 9
New AbbVie Growth Platform Provides Top-Tier Revenue Growth
2018 – 2023 Revenue CAGR
Expect High-Single
Digit Growth
10%

9%
9.2%
8%

7%

6%

5%

4%
4.4% 4.4% 4.2% Peer Average 3.1%
3%
3.4% 3.2% 3.1% 2.9%
2%
1.9%
1%
1.0%
0%
0.0% -0.1%
-1%
New AZN GSK BMY MRK ROG JNJ SAN PFE LLY GILD NVS AMGN
AbbVie
Growth
Platform

Growth Platform plus pipeline expected

to drive attractive revenue growth through 2023 and beyond

Peer growth calculated from analysts’ consensus estimates as of June 21, 2019. GSK revenue estimates sourced from Bloomberg, all other peer company 10
revenue estimates based on Nasdaq IR. New AbbVie non-Humira revenue growth range based on company estimates.
Potential for Substantial Value Creation
 The transaction offers significant and immediate accretion* and an attractive ROIC
• Expect 10% accretion over the first year of combination, with peak accretion of greater than 20%
• Expect >$2BN in annual pre-tax synergies and cost savings** in year 3 while protecting funding in
key growth franchises
• ROIC expected to exceed AbbVie cost of capital within first full year

 Supports AbbVie’s top- and bottom-line performance through Humira U.S. LOE
• New Growth Platform revenue of more than $30BN*** in 2020 expected to grow at high-single
digits through next decade at attractive operating margin profile

 Generates significant operating cash flows ($19BN in combined 2018 cash flow)
• Committed to Baa2/BBB credit rating or better and debt paydown; plan to reduce debt by $15-
18BN by 2021 with further de-leveraging through 2023
• Allows for continued flexibility for business development to augment innovative pipeline
• Enables the company to maintain an attractive dividend growth policy

 Integration of the two companies will be highly executable

• Major growth franchises untouched by integration activities, allowing them to exclusively focus on
maximizing performance
• Both companies have considerable experience in the integration of large, complex transactions

Significant shareholder value to be unlocked via the transaction, offering the

opportunity for stock re-rating
*The statement that this transaction is earnings accretive should not be interpreted to mean that the earnings per share in the current or any future financial
period will necessarily match or be greater than those for the relevant preceding financial period. **Represents annual synergies reached after 3 years post-close. 11
Synergy statement has been prepared in accordance with Irish Takeover Rules. ***Not intended as revenue guidance; See disclosure statement on Slide 3.
Commercial Presence
Market Leadership in Attractive, Growth Markets

#1 #2 #1
Position in Position in Position in
Immunology Hematologic Medical
Oncology Aesthetics

Leadership #1 Leadership
Position in Position in Position in
Women’s Health Global HCV Eye Care

13
 Immunology
Developing Industry-Leading Portfolio of Transformational Therapies to Address
Large and Growing $65BN* Market

Current–2020 2021–2023 2023+

LAUNCH PIPELINE AND INDICATION DELIVER THE NEXT ADVANCE THE NEXT
MAXIMIZE HUMIRA EXPANSION TRANSFORMATIVE GENERATION
THERAPY OF INNOVATION

 Achieve approvals with  Accelerate SKYRIZI and UPA  Advance early-stage  Advance the pre-clinical
differentiated labels for growth by gaining approvals programs exploring pipeline to drive the next
SKYRIZI in psoriasis and and demonstrating best-in- innovative molecules and generation of innovation:
Upadacitinib (UPA) in RA class potential in follow-on novel targets:
indications: • >20 ongoing preclinical
 Secure rapid and broad • ABBV-3373 (Rheum) projects
formulary access • SKYRIZI: CD, UC, PsA, AD, HS
• ABBV-599 (Rheum)
 Drive meaningful revenue • UPA: PsA, AD, CD, UC, GCA,
beginning in 2020; expect Axial SpA • ABBV-157 (Derm)
SKYRIZI and UPA to deliver • ABBV-323 (Gastro)
$>1BN in 2020
 Maximize Allergan’s
gastroenterology franchise

*Based on Evaluate Pharma. 14

Hematologic Oncology
Established Market Leadership Position in $40BN* Hematologic Malignancies Market

Develop Imbruvica and Venclexta as Launched: 2016

1 essential treatments in optimizing patient
outcomes across multiple hematologic
malignancies  First-in-class BTK inhibitor
 4 FDA Breakthrough Therapy
Transform the therapeutic approach, designations
allowing patients to achieve more
 10 approved indications across 6
2 durable, deeper responses, including the
option for some patients to stop distinct patient populations
treatment

Launched: 2016
Drive better long-term control of
3 hematological malignancies, ideally with
chemotherapy-free regimens
 First-in-class Bcl-2 inhibitor
 5 FDA Breakthrough Therapy
designations
Build a broader, deeper pipeline by  4 approved indications across CLL
4 leveraging our experience in apoptosis
and B Cell signaling
and AML populations

*Based on Evaluate Pharma and Kantar Health’s CancerMpact. 15

Medical Aesthetics
Leadership in an Attractive and Growing $12BN* Market

New product introduction and global expansion will drive

significant growth for Medical Aesthetics business

Aesthetics Market Launch 1-2 New Products Per Year

Growth Catalysts Over Next Several Years

 Increasing interest and acceptability of  Botox Cosmetic – expand new indications,

aesthetics formulations, configurations and delivery
technologies
 Global expansion and increasing international
penetration  Juvederm Collection of Fillers – Expand
indications and geographies; Develop next-
 Largest sales and marketing effort and market generation of fillers
leading promotional programs in aesthetics
expected to drive continued growth  CoolSculpting – Launch 3 upgrades in next 3
years, significantly expand customer base

*Based on Markets and Markets Medical Aesthetics Report September 2018. 16

 Neuroscience
Allergan Product Portfolio Provides Immediate Scale to AbbVie

Allergan AbbVie

 Duopa has established AbbVie presence in

 Vraylar continues to be the fastest growing
the advanced Parkinson’s disease market
branded antipsychotic
• Recently approved for bipolar depression • ABBV-951 in Phase 3 development as a
less-invasive, non-surgical delivery
• Represents a clear blockbuster option; potential to broaden the patient
opportunity in mood disorders; potential population and strengthen AbbVie’s
expansion into additional indications position in the advanced PD segment

 AbbVie is investing to become a market

 Botox Therapeutic driving durable growth leader in treating neurodegenerative
across all indications (chronic migraine, diseases
OAB and adult and pediatric spasticity)
• Advancing technologies & translational
capabilities to de-risk and accelerate
development

 Allergan is building on Botox leadership in  Evaluating new areas of disease biology to

migraine market with ubrogepant and address the growing unmet need in
atogepant Alzheimer’s and Parkinson’s Disease
 Oral CGRPs in late-stage development for • Focus on misfolded proteins,
acute treatment and prevention of neuroinflammation and proteostasis
episodic and chronic migraine • ABBV-8E12 (AD); ABBV-0805 (PD)

17
Other Key Franchises
Market Leadership Positions in HCV, Women’s Health and Eye Care

HCV Women’s Health

 HCV represents large global market, sustainable  Elagolix represents significant advance for
into the mid-2020s women suffering from endometriosis and
uterine fibroids
 Mavyret holds leadership position; emphasis on
addressing the remaining unmet medical need  Orilissa expected to be a significant
product; revenue of >$2BN by 2025
 Mavyret will remain a strong source of cash
flow over our long range plan period  Leverage commercial scale to drive strong,
profitable growth for market leading oral
contraceptive, Lo Loestrin

Eye Care Stable Base Business

 Durable $2BN* franchise (ex-Restasis) with  Sales from legacy products are well
multiple late-stage pipeline opportunities positioned for durable performance going
 Expanding presence by targeting unmet needs forward
in retinal disease  Profitable businesses with minimal opex
 Innovate in glaucoma to drop-less therapy generate durable cash flows

*Eye Care revenue represents Allergan 2018 Eye Care revenue excluding Restasis revenue of $1.262 billion. 18
AbbVie Commercial Excellence

• Senior Management experience running diverse

healthcare businesses
30 million +
Patients treated by AbbVie’s • Strong track record of commercial execution
medicines every year
• Commercial experience building and maintaining
industry-leading franchises
• Exceptional support programs for patients
175+ and caregivers
Countries where AbbVie’s
products help patients

2.3 million
Patients impacted through
AbbVie patient support
programs globally

19
Attractive Pipeline
Opportunities
 Transaction Allows for Continued Strong Investment in
Promising, Innovative Science
Annual R&D Investment* Designations Granted

14 Breakthrough Designations

10 Fast Track Designations

4 Accelerated Approvals

19 Priority Reviews

Major AbbVie Product and Indication Approvals Since 2013

Immunology 3 Approvals
Oncology 6 Approvals
13 FDA
Approvals Neuroscience 1 Approval
Virology 2 Approvals
Women's Health 1 Approval
*Adjusted R&D Investment

21
 AbbVie’s Strong Pipeline Augmented with Numerous
Attractive Opportunities
Phase 1 Phase 2 Registrational/Phase 3 Recent Approvals
ABBV-011: SCLC Venclexta: MDS Venclexta: MM, MCL Venclexta: 1L CLL, R/R CLL, AML (1L)
Mivebresib: Solid Tumors Navitoclax: Myelofibrosis Imbruvica: FL (1L), FL/MZL (R/R), MCL (1L) Imbruvica + Rituximab: WM
ABBV-085: Solid Tumors Teliso-V: Solid Tumors Empliciti: MM (1L)
Skyrizi: Psoriasis
ABBV-155: Solid Tumors ABT-165: Solid Tumors Veliparib: NSCLC, BRCA Breast, Ovarian
ABBV-151: Solid Tumors Rova-T: SCLC (1L) Orilissa: Endometriosis
Risankizumab: AD, HS
ABBV-167:Solid Tumors and Blood Cancers
Upadacitinib: Axial SpA Risankizumab: CD, UC, PsA
ABBV-181: Solid Tumors
ABBV-599: RA Upadacitinib: RA (filed), PsA, CD, UC, AD,
ABBV-321: Solid Tumors
AbbVie

ABBV-323: UC GCA
ABBV-368: Solid Tumors
ABBV-3373: RA (P1b/2a) Imbruvica: cGvHD (1L)
ABBV-621: Solid Tumors
Humira: Pyoderma Gangrenosum (Japan)
ABBV-744: Solid Tumors and Blood Cancers ABBV-8E12: Alzheimer’s Disease, PSP Oncology
ABBV-927: Solid Tumors Elezanumab: MS ABBV-951: Parkinson’s Disease
ABBV-2029: Solid Tumors Immunology
ABBV-2222/3067: Cystic Fibrosis Elagolix: Uterine Fibroids
ABBV-647: Solid Tumors
Neuroscience
Venclexta: ALL
Targeted Investment
ABBV-157: Ps
ABBV-154: RA

ABBV-0805: Parkinson’s Disease

ABBV-3903: Cystic Fibrosis

Botox: Skin Quality BoNTE: Glabellar Lines NivobotulinumtoxinA: Facial Lines Cariprazine: Bipolar Depression
Botox: Masseter, Platysma
AGN-151607: MDD Atogepant: Migraine Prophylaxis
Deoxycholic Acid: Jowl Fat Reduction
Cariprazine: Autism Spectrum Disorder Ubrogepant: Acute Migraine Treatment
AGN-242626: Alzheimer’s Disease AGN-241751: MDD Cariprazine: Adjunctive MDD
AGN-242071: Alzheimer’s Disease
Optive Ultra: Dry Eye Presbysol: Presbyopia
Allergan

Medical Aesthetics
Optive Lite MDPF: Dry Eye Brimonidine DDS: Geographic Atrophy, Bimatoprost SR: Glaucoma
AGN-151597: Retinitis Pigmentosa Glaucoma Neuroprotection Optive Fusion: MDPF Neuroscience
Bimatoprost Ring: Glaucoma Abicipar: AMD
AGN-242266: NASH Eye Care
Abicipar: DME
Relamorelin: Diabetic Gastroparesis
Gastrointestinal
Cenicriviroc + Tropifexor: NASH Cenicriviroc: NASH
Linaclotide Delayed Release: IBS Pain Targeted Investment

AGN-151607: Atrial Fibrillation

As of June 25, 2019. This pipeline represents only medicines; It does not include devices currently in development. 22
Includes programs that may be discontinued and included in synergies if data do not meet acceptable criteria.
Shareholder Value
Creation
Synergies Generate Significant Value
Percent of Total Synergies and
Areas of Opportunity
Cost Reductions

SG&A
SG&A • Sales and marketing efficiencies
~40%
• Reduce duplicate costs across central
support functions & IT systems

R&D
Manufacturing &
Supply Chain ~10% >$2BN • Optimize research & early-stage portfolio
in Year 3
• Reduce overlapping resources
R&D
~50% Manufacturing & Supply Chain
• Leverage procurement spend
• Optimize overhead with combined global
footprint

Key franchise funding levels will remain untouched allowing them to maximize performance

Integration will be highly executable as both companies have considerable experience with the
integration of large, complex transactions

*Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules. 24
Balance Sheet Strength Will Be Preserved With Robust Cash Flows

Transaction Financing Robust Cash Flow to Reduce Debt

 Transaction supported with a $38BN fully  AbbVie affirms its commitment to Baa2/BBB
underwritten bridge facility obtained from grade credit rating or better
Morgan Stanley and MUFG
• Humira cash flow generation exceeds
incremental financing prior to U.S. loss of
 The combined company will generate strong exclusivity, will be utilized to pay off
durable operating cash flow ($19BN in acquisition financing
combined 2018 cash flow)
• Committed to reduce debt by $15BN to
• Supports AbbVie’s commitment to a strong $18BN before end of 2021, with further
de-leveraging through 2023
growing dividend
• Credit metrics targeted to improve to 3.0X
• Provides resources for continued expansion net debt to EBITDA in the near term and
of AbbVie’s innovative pipeline through improve in subsequent years
increased R&D funding and mid-to-late
stage asset additions

25
 AbbVie Has a Track Record of Strong Execution, Consistently
Meeting or Exceeding Financial Commitments

• Ranked 1st or 2nd in our peer group for both revenue and adjusted EPS growth in every year
since becoming an independent company*
Consistently delivered
• Met or exceeded both revenue and adjusted EPS guidance in all 25 quarters since becoming
industry leading financial an independent company
performance • Ranked in top decile of our peer group for operating cash flow growth and adjusted return
on equity over past six years

• Led our peer group in total shareholder return, delivering total returns of 190%** since
Delivered Outstanding becoming an independent company
Shareholder Value • Increased quarterly dividend by 168% since becoming an independent company; member of
and Return of Cash the S&P Dividend Aristocrats Index
• Returned nearly $44BN to investors via dividends and share repurchases

Built Market Leadership • We’ve built a strong leadership position in the Immunology market with Humira and
continue to innovate with our two next-generation immunology assets
Positions and Delivered
• Built a tremendous growth platform in Heme-Onc with Imbruvica and Venclexta, assets that
New and Improved are capable of transforming treatment across a wide range of blood cancers
Therapies • Became a global HCV leader with launch of Mavyret, our next-generation HCV cure

Consistently Increased • 13 new product or major indication approvals since becoming an independent company
Investment and • $5.1BN in adjusted R&D spend in 2018, growth of over 80% since 2013
Productivity in the R&D • Built a robust pipeline with 60+ active clinical development programs with more than 30 new
Pipeline products or indications in mid-and late-stage development or under regulatory review

*Measured over the past 1, 2, 3, 4, 5 years or since separation, with, as 2012 pro forma AbbVie EPS is not available, EPS growth referring to the periods
from 2013. **Total shareholder return January 1, 2013 through June 19, 2019.
26
Combination Creates Diversified Biopharmaceutical Company,
Well-Positioned for Sustainable Growth

Unique
opportunity to
Provides
acquire highly Potential for
immediate scale Deal significantly
attractive and substantial
and profitability to mitigates 2023
durable growth shareholder value
AbbVie’s Growth U.S. Humira LOE
assets at a highly creation
Platform
compelling value

Creates Generates >$2BN Significant EPS Accretion:

Significant ROIC to Exceed AbbVie
in Synergies and 10% Accretion Over the First
Cost of Capital Within
Shareholder Cost Savings Full Year of Combination
First Full Year
Value in Year 3* Peaking at >20%**

*Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules. * * The statement
that this transaction is earnings accretive should not be interpreted to mean that the earnings per share in the current or any future financial period will necessarily 27
match or be greater than those for the relevant preceding financial period.